
Neurocrine Biosciences (NBIX) Stock Forecast & Price Target
Neurocrine Biosciences (NBIX) Analyst Ratings
Bulls say
Neurocrine Biosciences is benefiting from robust commercial execution, with 3Q26 revenue of $1.12 billion rising 41% year over year as Ingrezza, Crenessity, and VYKAT XR all beat expectations and drove non-GAAP diluted EPS of $3.3. Ingrezza remains the anchor, as ~$801 million in sales, record prescriptions, and a raised FY26 guide to $2.9 billion-$2.925 billion support another year of growth despite expected pricing pressure, while 2027 access looks at least as strong as 2026 and volume should still outpace net price erosion. Crenessity’s ~$211 million quarter, >$800 million annualized run rate, and low penetration in classic CAH leave substantial runway, and the pipeline adds further upside through multiple 2027 readouts in psychiatry, VMAT2, and CAH.
Bears say
Neurocrine Biosciences is exposed to meaningful downside if Ingrezza and Crenessity grow more slowly than expected, if Vykat XR also underperforms, or if new competitors and pricing pressure erode market share and pricing power. The outlook is further weakened by the possibility of real-world safety signals, changing physician preferences versus Austedo, and regulatory or clinical setbacks that could delay or derail pipeline assets. In a downside scenario, those pressures could reduce estimates materially, with one DCF-based valuation cited at $85, while partnership disruptions and failure of ongoing trials add additional execution risk.
This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Neurocrine Biosciences (NBIX) Forecast
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares